摘要 免疫性血小板减少症(immune thrombocytopenia,ITP)是一种获得性自身免疫性疾病,其主要机制为血小板破坏过多及生成受阻导致血小板计数减少。一般人群中ITP的发病率为2/10万~5/10万。新版指南提供了儿童ITP一线和二线治疗方案,一线治疗方案包括观察、门诊、皮质类固醇、抗D免疫球蛋白、静脉注射免疫球蛋白(intravenous immunoglobulin,IVIG),二线治疗方案包括利妥昔单抗、血小板生成素受体激动剂(thrombopoietin receptor agonists,TPO-RA)、脾切除术。另有一些三线药物治疗但指南未给出明确建议。 Immune thrombocytopenia(ITP)is an acquired autoimmune disorder characterized by a low platelet count resulting from platelet destruction and impaired platelet production. The incidence of ITP is estimated to be 2 to 5 per 100 000 persons in the general population. The latest guidelines offer first-and second-line treatments for ITP in children. The first-line treatment options include observation,outpatient visit,corticosteroids,anti-D immunoglobulin and intravenous injection of immunoglobulin(IVIG). The second-line treatments include rituximab,thrombopoietin receptor agonists(TPO-RA)and splenectomy. There are other third-line treatments,for which the guidelines do not make clear recommendations.
出处 《中国实用儿科杂志》 CSCD 北大核心 2021年第2期81-85,共5页 Chinese Journal of Practical Pediatrics
分类号 R72 [医药卫生—儿科]
